Ormeloxifene versus Tranexamic Acid in the management of abnormal uterine bleeding due to uterine leiomyoma(AUB-L) - NI

Jenni Mariam George0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Women in the reproductive age group who have completed their family or unmarried women not desirous of conception, with heavy menstrual bleeding due to uterine fibroids.
•Women with a pretreatment PBAC Score of more than or equal to 100.

•1. Irregular menstrual bleeding
•2. Adnexal mass
•3. Acute heavy bleeding necessitating hospitalization and immediate treatment with hormones
•4. breast or genital tract malignancy,
•5. Patients who are unable to followup after 3-6 months
•6. Cervical dysplasia
•7. Adenomyosis/endometrial polyp
•8. Bleeding dyscrasias
•9. Clinical evidence of jaundice or hepatic dysfunction, renal, cardiac or metabolic disorders
•10. Known hypersensitivity to Tranexamic acid
•11. Patients previously treated with Ormeloxifene
•12. Women desirous of fertility
•13. Patients on concurrent treatment with other drugs for AUB

发起方

Jenni Mariam George